A live webcast of ACADIA's presentation will be accessible on thecompany's website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through December 17, 2008.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA is focused on developing aportfolio of its four most advanced product candidates, includingpimavanserin in Phase III for Parkinson's disease psychosis, a productcandidate in Phase II for chronic pain and a product candidate in PhaseI for glaucoma, both in collaboration with Allergan, and ACP-106 inIND-track development. All of the product candidates in ACADIA'spipeline emanate from discoveries made using its proprietary drugdiscovery platform. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.
SOURCE: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President andChief Financial Officer
858-558-2871